Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Fingolimod provides long‐term protection in rodent models of cerebral ischemia

Open access
Wei, Ying, Yemisci, Muge, Kim, Hyung‐Hwan, Yung, Lai Ming, Shin, Hwa Kyoung, Hwang, Seo‐Kyoung, Guo, Shuzhen, Qin, Tao, Alsharif, Nafiseh, Brinkmann, Volker, Liao, James K, Lo, Eng H, Waeber, Christian·2011·Annals of Neurology

Abstract

Objective: The sphingosine‐1‐phosphate (S1P) receptor agonist fingolimod (FTY720), that has shown efficacy in advanced multiple sclerosis clinical trials, decreases reperfusion injury in heart, liver, and kidney. We therefore tested the therapeutic effects of fingolimod in several rodent models of focal cerebral ischemia. To assess the translational significance of these findings, we asked whether fingolimod improved long‐term behavioral outcomes, whether delayed treatment was still effective, and whether neuroprotection can be obtained in a second species. Methods: We used rodent models of middle cerebral artery occlusion and cell‐culture models of neurotoxicity and inflammation to examine the therapeutic potential and mechanisms of neuroprotection by fingolimod. Results: In a transient mouse model, fingolimod reduced infarct size, neurological deficit, edema, and the number of dying cells in the core and periinfarct area. Neuroprotection was accompanied by decreased inflammation, as fingolimod‐treated mice had fewer activated neutrophils, microglia/macrophages, and intercellular adhesion molecule‐1 (ICAM‐1)‐positive blood vessels. Fingolimod‐treated mice showed a smaller infarct and performed better in behavioral tests up to 15 days after ischemia. Reduced infarct was observed in a permanent model even when mice were treated 4 hours after ischemic onset. Fingolimod also decreased infarct size in a rat model of focal ischemia. Fingolimod did not protect primary neurons against glutamate excitotoxicity or hydrogen peroxide, but decreased ICAM‐1 expression in brain endothelial cells stimulated by tumor necrosis factor alpha. Interpretation: These findings suggest that anti‐inflammatory mechanisms, and possibly vasculoprotection, rather than direct effects on neurons, underlie the beneficial effects of fingolimod after stroke. S1P receptors are a highly promising target in stroke treatment. ANN NEUROL, 2010

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.22186

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 277

Metadata

Authors
Wei, Y., Yemisci, M., Kim, H., Yung, L. M., Shin, H. K., Hwang, S., Guo, S., Qin, T., Alsharif, N., Brinkmann, V., Liao, J. K., Lo, E. H., & Waeber, C.
Venue
Annals of Neurology
Publisher
Wiley
Published
2010-11-12
Volume
69
Issue
1
Pages
119-129
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2137571200
Cited by
277
References
45
FWCI
9.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fingolimod provides long‐term protection in rodent models of cerebral ischemia. https://app.cochat.ai/papers/10.1002/ana.22186
The paper
Wei, Y., Yemisci, M., Kim, H., Yung, L. M., Shin, H. K., Hwang, S., Guo, S., Qin, T., Alsharif, N., Brinkmann, V., Liao, J. K., Lo, E. H., & Waeber, C. (2011). Fingolimod provides long‐term protection in rodent models of cerebral ischemia. Annals of Neurology. https://doi.org/10.1002/ana.22186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.